OBJECTIVE: Resistance to chemotherapy is a major challenge in the treatment of ovarian/peritoneal cancer. One purported mechanism of topotecan resistance is the breast cancer resistance protein (BCRP) and P-glycoprotein (Pgp). We designed a phase II clinical trial evaluating the efficacy and adverse event profile of concomitant topotecan and lapatinib, a small molecule pan-erbB inhibitor that can block BCRP/Pgp efflux of topotecan. METHODS: Patients with platinum-refractory or resistant epithelial ovarian/peritoneal cancer were treated with topotecan 3.2 mg/m² IV on Day 1, 8 and 15 and lapatinib 1250 mg PO daily, continuously in 28 day cycles. The primary endpoint was response rate. For correlative studies, archived tissue was assessed for expression of EGFR, HER2, HIF-1α, CD31, and BCRP. RESULTS: Eighteen patients were enrolled and treated. Four experienced evidence of clinical benefit: one partial response and three with stable disease. Using a two-stage Simon design, the trial was stopped after the first stage due to insufficient activity. Grades 3+ and 4+ adverse events (AE) were experienced in 14 and 4 patients, respectively. The most common grade 3/4 AE were neutropenia (56%), thrombocytopenia (28%), and diarrhea (22%). CONCLUSIONS: The combination of lapatinib plus topotecan for the treatment of platinum refractory/resistant epithelial ovarian cancer lacks sufficient activity to warrant further investigation. In particular, hematologic adverse events were substantial. Expression of correlative study markers did not reveal patterns of predicted benefit or toxicity. Disruption of erbB signaling and BCRP/Pgp efflux with lapatinib was insufficient for overcoming topotecan resistance, suggesting alternative mechanisms of resistance are involved.
OBJECTIVE: Resistance to chemotherapy is a major challenge in the treatment of ovarian/peritoneal cancer. One purported mechanism of topotecan resistance is the breast cancer resistance protein (BCRP) and P-glycoprotein (Pgp). We designed a phase II clinical trial evaluating the efficacy and adverse event profile of concomitant topotecan and lapatinib, a small molecule pan-erbB inhibitor that can block BCRP/Pgp efflux of topotecan. METHODS:Patients with platinum-refractory or resistant epithelial ovarian/peritoneal cancer were treated with topotecan 3.2 mg/m² IV on Day 1, 8 and 15 and lapatinib 1250 mg PO daily, continuously in 28 day cycles. The primary endpoint was response rate. For correlative studies, archived tissue was assessed for expression of EGFR, HER2, HIF-1α, CD31, and BCRP. RESULTS: Eighteen patients were enrolled and treated. Four experienced evidence of clinical benefit: one partial response and three with stable disease. Using a two-stage Simon design, the trial was stopped after the first stage due to insufficient activity. Grades 3+ and 4+ adverse events (AE) were experienced in 14 and 4 patients, respectively. The most common grade 3/4 AE were neutropenia (56%), thrombocytopenia (28%), and diarrhea (22%). CONCLUSIONS: The combination of lapatinib plus topotecan for the treatment of platinum refractory/resistant epithelial ovarian cancer lacks sufficient activity to warrant further investigation. In particular, hematologic adverse events were substantial. Expression of correlative study markers did not reveal patterns of predicted benefit or toxicity. Disruption of erbB signaling and BCRP/Pgp efflux with lapatinib was insufficient for overcoming topotecan resistance, suggesting alternative mechanisms of resistance are involved.
Authors: Sheng Zhou; John J Morris; Yuxiao Barnes; Lubin Lan; John D Schuetz; Brian P Sorrentino Journal: Proc Natl Acad Sci U S A Date: 2002-09-06 Impact factor: 11.205
Authors: C Erlichman; S A Boerner; C G Hallgren; R Spieker; X Y Wang; C D James; G L Scheffer; M Maliepaard; D D Ross; K C Bible; S H Kaufmann Journal: Cancer Res Date: 2001-01-15 Impact factor: 12.701
Authors: F Ciardiello; R Caputo; R Bianco; V Damiano; G Pomatico; S De Placido; A R Bianco; G Tortora Journal: Clin Cancer Res Date: 2000-05 Impact factor: 12.531
Authors: S Zhou; J D Schuetz; K D Bunting; A M Colapietro; J Sampath; J J Morris; I Lagutina; G C Grosveld; M Osawa; H Nakauchi; B P Sorrentino Journal: Nat Med Date: 2001-09 Impact factor: 53.440
Authors: H D Homesley; D J Hall; D A Martin; G S Lewandowski; L Vaccarello; W A Nahhas; C L Suggs; R G Penley Journal: Gynecol Oncol Date: 2001-11 Impact factor: 5.482
Authors: H Zhong; A M De Marzo; E Laughner; M Lim; D A Hilton; D Zagzag; P Buechler; W B Isaacs; G L Semenza; J W Simons Journal: Cancer Res Date: 1999-11-15 Impact factor: 12.701
Authors: P de Graeff; A P G Crijns; S de Jong; M Boezen; W J Post; E G E de Vries; A G J van der Zee; G H de Bock Journal: Br J Cancer Date: 2009-06-09 Impact factor: 7.640
Authors: Jonathan Stewart; Jacqueline James; Glenn W McCluggage; Stephen McQuaid; Kenneth Arthur; David Boyle; Paul Mullan; Darragh McArt; Benedict Yan; Gareth Irwin; D Paul Harkin; Lei Zhengdeng; Chee-Wee Ong; Jia Yu; David M Virshup; Manuel Salto-Tellez Journal: Mod Pathol Date: 2014-09-26 Impact factor: 7.842
Authors: Henry D Reyes; Kristina W Thiel; Matthew J Carlson; Xiangbing Meng; Shujie Yang; Jean-Marie Stephan; Kimberly K Leslie Journal: Mol Diagn Ther Date: 2014-04 Impact factor: 4.074
Authors: Clinton F Stewart; Michael Tagen; Lee S Schwartzberg; L Johnetta Blakely; Kurt W Tauer; Linda M Smiley Journal: Cancer Chemother Pharmacol Date: 2014-01-22 Impact factor: 3.333
Authors: Jason A Wilken; Tayf Badri; Sarah Cross; Rhoda Raji; Alessandro D Santin; Peter Schwartz; Adam J Branscum; Andre T Baron; Adam I Sakhitab; Nita J Maihle Journal: Future Med Chem Date: 2012-03 Impact factor: 3.808
Authors: Jerec W Ricci; Debbie M Lovato; Virginia Severns; Larry A Sklar; Richard S Larson Journal: Mol Cancer Ther Date: 2016-09-26 Impact factor: 6.261
Authors: Marc A Becker; Thahir Farzan; Sean C Harrington; James W Krempski; S John Weroha; Xiaonan Hou; Kimberly R Kalli; Tai W Wong; Paul Haluska Journal: Mol Cancer Ther Date: 2013-10-15 Impact factor: 6.261
Authors: Elisabeth Smolle; Valentin Taucher; Martin Pichler; Edgar Petru; Sigurd Lax; Johannes Haybaeck Journal: Int J Mol Sci Date: 2013-05-02 Impact factor: 5.923